Literature Scan

Literature Scan

New and noteworthy research from the medial literature landscape

Can Adding Lenalidomide to Rituximab-MiniCHOP Improve Survival in Older Patients With Diffuse Large B-Cell...

In a phase III trial of patients age 80 or older with diffuse large B-cell lymphoma (DLBCL), attempts to improve on the standard approach...

Predicting CAR T-Cell Treatment Failure in Patients With Aggressive B-Cell Lymphomas

Nearly one-half of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are treated with chimeric antigen receptor (CAR) T-cell therapy experience a relapse...

Moving Beyond Gene Rearrangements to Define High-Risk Diffuse Large B-Cell Lymphoma

In diffuse large B-cell lymphoma (DLBCL), patients typically are risk-stratified according to cell-of-origin, but recent genetics-based classifications led the World Health Organization to establish...

Pegcetacoplan Improves Hematologic Response in PNH Treated With Eculizumab

For patients with paroxysmal nocturnal hemoglobinuria (PNH) who are receiving eculizumab yet have residual anemia, treatment with pegcetacoplan led to broad hemolysis control and...

What Is the Best Method for Cytoreduction in Patients With Acute Myeloid Leukemia and...

In patients with acute myeloid leukemia (AML), hyperleukocytosis is associated with the oncologic emergency leukostasis as well as inferior outcomes, but there are few...

BOSTON: Selinexor Improves Progression-Free Survival in Relapsed/Refractory Myeloma

The combination of once-weekly selinexor with bortezomib and dexamethasone (SVd) demonstrated a 30% reduction in the risk of disease progression or death, compared with...

Imetelstat Improves Rate of Durable Transfusion Independence in Patients With Lower-Risk MDS

Treatment with imetelstat, a competitive inhibitor of telomerase enzymatic activity, was associated with a clinically meaningful rate of transfusion independence in heavily transfused patients...

Precision Medicine Approach Deemed Safe, Feasible for Older Patients With Untreated AML

A precision medicine treatment approach that incorporates genomic data into treatment decisions appears to be feasible in older patients with untreated acute myeloid leukemia...

Ivosidenib and Azacitidine Combination Demonstrates Durable Activity in Newly Diagnosed AML

Ivosidenib, an inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1) enzyme, was well tolerated and associated with deep and durable responses in combination with...

Study Identifies Key Mutations That Promote Stem Cell Growth and Increase Leukemia Risk

In a report published in Nature, researchers linked three genetic loci to the increased proliferation of hematopoietic stem cells (HSCs), which may subsequently increase...
Advertisement

Current Issue

May 2021 Volume 7 Issue 6

This issue provides an update on gene therapies in hematology, demystifies RNA sequencing, and more.

Block title